Enhertu Nabs A First With UK Standalone Approval
Advanced Breast Cancer Treatment Is First New Cancer Drug Approved In 2021
Executive Summary
The UK conditional approval of Daiichi Sankyo/AstraZeneca’s advanced breast cancer drug Enhertu was issued in accordance with “transitional provisions” that apply to drugs that received a positive opinion from the European Medicines Agency before the end of the Brexit transition period.
You may also be interested in...
Mainstays Give And Take As Major Japan Firms Report Results
While Daiichi Sankyo reveals ambitious plan with Enhertu, Chugai shows stable growth plans with COVID-19 drugs, Astellas reacted to concerns over Xtandi’s slow growth with enthusiastic investment plan for the next potential star.
NICE Funding Wins For Enhertu & Kesimpta Are Firsts For England
UK health technology assessment body NICE has struck deals with the makers of Enhertu for advanced breast cancer and Kesimpta for relapsing forms of multiple sclerosis.
Seagen Debuts In EU With Tukysa Launch & Sees UK As 'Key' Future Market
Tuomo Pätsi of US biotech firm Seagen discusses plans for the rollout of Tukysa in Europe, how it successfully used a new mechanism for approval in Great Britain, and why the UK will be a go-to market for future innovative drug filings.